Journal profile · Pharmacology & Pharmacy
European Journal of Pharmaceutics and Biopharmaceutics
ISSN 0939-6411 · eISSN 1873-3441 · Elsevier · NETHERLANDS · Bimonthly · Founded 1991
European Journal of Pharmaceutics and Biopharmaceutics: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.95; hybrid open access; APC about USD 4,210; median 94 days to acceptance (107 articles, last 24 months); community-reported acceptance: 66%; 272 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
European Journal of Pharmaceutics and Biopharmaceutics is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Drug Solubulity and Delivery Systems, Advanced Drug Delivery Systems and Advancements in Transdermal Drug Delivery, together about 37.5% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
Official journal of the International Association for Pharmaceutical TechnologyThe European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.Topics covered include for example:Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)Aspects of manufacturing process designBiomedical aspects of drug product designStrategies and formulations for controlled drug transport across biological barriersPhysicochemical aspects of drug product developmentNovel excipients for drug product designDrug delivery and controlled release systems for systemic and local applicationsNanomaterials for therapeutic and diagnostic purposesAdvanced therapy medicinal productsMedical devices supporting a distinct pharmacological effect"The Rules of 3"The Editors and Editorial board have developed the "Rules of 3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work: The paper must report on novel findings that are not merely an unprecedented combination of known aspects in pharmaceutics and biopharmaceutics of major importance. The paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.The study described in the manuscript must not merely confirm the state of the art in the field of pharmaceutics and biopharmaceutics, but advance it.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief M. BreunigPublisher website
Editorial board by country: 19 in mainland China (about 12%); most named Germany 33, United States 24, Mainland China 19, United Kingdom 11, Spain 8 (157 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics15.2%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics13.9%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics8.5%
- Nanoparticle-Based Drug DeliveryMaterials Science6.3%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology5.5%
- Protein purification and stabilityBiochemistry, Genetics and Molecular Biology4.9%
- Human auditory perception and evaluationEngineering4%
- Inhalation and Respiratory Drug DeliveryMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.95LetPub ·
- Impact factor (publisher)
- 5Publisher website ·
- CiteScore 2026-06
- 8.1LetPub ·
- CiteScore (publisher)
- 8.1Publisher website ·
- SJR 2026-06
- 0.85LetPub ·
- SNIP 2026-06
- 0.98LetPub ·
- h-index
- 138LetPub ·
- h-index
- 212OpenAlex ·
- i10-index
- 4,885OpenAlex ·
- 2-year mean citedness
- 5.45OpenAlex ·
- Self-citation rate
- 4%LetPub ·
- Share of gold OA articles
- 34.91%LetPub ·
Volume
- Articles per year
- 241LetPub ·
Articles by year OpenAlex count · 7,037 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 199 | 79 | 92 |
| 2025 | 272 | 107 | 967 |
| 2024 | 341 | 172 | 3,367 |
| 2023 | 260 | 105 | 3,909 |
| 2022 | 237 | 99 | 4,283 |
| 2021 | 226 | 92 | 6,389 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
94 daysMedian, submission to acceptance · P25–P75 74 days – 117 days
- Acceptance to online
- median 1 days (107 articles)
- Submission to online
- median 98 days
- Sample
- 107 articles with submission and acceptance dates (550 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 66%LetPub ·
- Submission to first decision
- 9 daysPublisher website ·
- First decision after review
- 53 daysPublisher website ·
- Submission to acceptance
- 117 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,210 / EUR 3,940 / GBP 3,370 / JPY 522,170 | — | — | |
| Publisher website | USD 3,780 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare4 items from the author guidelines
- Abstract
- ≤ 200 words
- Keywords
- ≥ 5
- Reference style
- Numbered, in order of citation
- Graphical abstract
- Required
Article types accepted7
- focus on meetingsThese types of papers focus on interesting and relevant topics that have been presented and evolved at meetings.Length not stated
- focus on methodsThese types of papers have the intention to inform about novel and innovative methods and techniques that are relevant to a broad readership and may help to ans…Length not stated
- graphical reviewsGraphical Reviews are short, structured articles that visually convey key concepts and novel ideas, or visually summarize current research within the fields of …Length not stated
- letter to the editorThis type of paper is an opportunity to voice the scientific opinion of researchers regarding a certain topic that is within the scope of the journal and availa…Length not stated
- perspectivesThis type of paper is by invitation only.Length not stated
- research papersResearch papers are reports of novel, innovative and hypothesis-driven original research from the area of Pharmaceutics, Biopharmaceutics and Biopharmaceutical …Length not stated
- review articlesReviews are of immediate relevance and provide a comprehensive summary of topics within the fields of Pharmaceutics, Biopharmaceutics and Biopharmaceutical tech…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Authorship requirements Model summary
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Ethics in publishing Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process; submissions initially assessed by editors; if suitable, sent to a minimum of two reviewers; decision made by editors. Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed; free preprint posting service on SSRN offered. Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1991
- ISSN
- 0939-6411
- Electronic ISSN
- 1873-3441
- Society / sponsor
- International Association for Pharmaceutical Technology
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about European Journal of Pharmaceutics and Biopharmaceutics
What CAS zone is European Journal of Pharmaceutics and Biopharmaceutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, European Journal of Pharmaceutics and Biopharmaceutics is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of European Journal of Pharmaceutics and Biopharmaceutics?
The latest impact factor listed by LetPub is 4.95; CiteScore 8.1, h-index 212.
How long does peer review take at European Journal of Pharmaceutics and Biopharmaceutics?
Based on the dates recorded on 107 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 94 days (interquartile range 74–117 days); authors report an average review time of about 3 months; the community-reported acceptance is “66%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of European Journal of Pharmaceutics and Biopharmaceutics?
According to the journal's author guidelines: Abstract: ≤ 200 words; Keywords: ≥ 5; Reference style: Numbered, in order of citation; Graphical abstract: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of European Journal of Pharmaceutics and Biopharmaceutics based?
Of the 157 board members whose country the journal's board page names, 19 (about 12%) are in mainland China; the countries named most often are Germany (33), United States (24) and Mainland China (19). Counted from the institutions listed on the board page; for reference only.
Which databases index European Journal of Pharmaceutics and Biopharmaceutics?
According to LetPub and DOAJ records, European Journal of Pharmaceutics and Biopharmaceutics is indexed in SCIE and Scopus.
Is European Journal of Pharmaceutics and Biopharmaceutics open access, and what is the APC?
European Journal of Pharmaceutics and Biopharmaceutics is a hybrid journal. For open-access publication: APC about USD 4,210.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .